Explore the power of
high-plex protein
profiling to your
cardiovascular disease

Discovery, validation, and development in a single proteomics platform

Gain deeper insights with proteomics

See you soon at AHA annual meeting In Philadelphia!

Join our scientific sessions (details below), and then stop by booth 2917 to experience the power of the SomaScan® Assay. We look forward to hearing about your cardiovascular disease (CVD) research needs and discussing how we can help advance your novel biomarker discoveries with our high-plex protein profiling platform.

Icon depicting group watching a presentation

Attend our
CVD talk

Michael Hinterberg, PhD, Senior Scientist from SomaLogic, shares findings on “Applying Proteomic CV and Kidney Prognosis Risk in T2D Patients to Identify High-Risk Patients.”

Icon depicting scientific posters

See our
5 CVD posters

Explore the latest research in cardiovascular disease using high-plex proteomics.

Icon depicting tradeshow booth

Stop by
booth 2917

Come by our booth to speak to our team and share more about your CVD research.

Michael A Hinterberg, PhD


Applying Proteomic CV and Kidney Prognosis Risk in Type 2 Diabetes (T2D) Patients to Identify High-Risk Patients

Sunday, Nov 12, 2023 | 8:30-8:45AM | Location: 204A

Presenter: Michael A. Hinterberg, PhD
Senior Scientist at SomaLogic

Join us Sunday to explore the interdependence of cardiovascular and kidney health in T2D. Proteomic surrogate models for cardiovascular risk and kidney prognosis have been developed and validated, but not in a combined manner in T2D patients.

Learn more at our poster sessions

Session Title Presenter Date and Time
Using the proteome to detect biomarkers of cardiovascular comorbidities Yolanda Hagar,
Saturday, Nov 11, 2023 3:00-4:15 PM
Statin signature: Using proteomics to detect pharmacological fingerprints Clare Paterson,
Monday, Nov 13, 2023 10:30-11:45 AM
Utilization of proteomic surrogates for early detection of unexpected drug benefits Steve Williams,
Monday, Nov 13, 2023 10:30-11:45 AM
Using a proteomics-based cardiovascular risk test to identify systemic changes in a clinical trial of nonalcoholic fatty liver disease Clare Paterson,
Monday, Nov 13, 2023 1:30-2:45 PM
Comparison of Proteomic CV Risk to Established ASCVD 10-year Risk Decision Points Michael A. Hinterberg, PhD Monday, Nov 13, 2023 1:30-2:45 PM


*Each poster presentation will be held in the Science & Technology Hall, Level 2, Hall A-D

Watch the SomaScan Assay in action